Combination therapy with androgen receptor N‐terminal domain antagonist EPI‐7170 and enzalutamide yields synergistic activity in AR‐V7‐positive prostate cancer

Resistance of castration‐resistant prostate cancer (CRPC) to enzalutamide and abiraterone involves the expression of constitutively active, truncated androgen receptor (AR) splice variants (AR‐Vs) that lack a C‐terminal ligand‐binding domain (LBD). Both full‐length AR and truncated AR‐Vs require a f...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirayama, Yukiyoshi, Tam, Teresa, Jian, Kunzhong, Andersen, Raymond J., Sadar, Marianne D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530779/
https://www.ncbi.nlm.nih.gov/pubmed/32734688
http://dx.doi.org/10.1002/1878-0261.12770

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7530779/
https://www.ncbi.nlm.nih.gov/pubmed/32734688
http://dx.doi.org/10.1002/1878-0261.12770

Ejemplares similares